# EpiBiologics funding rounds and investors

As of 14 Oct 2026, EpiBiologics has raised $107M across 1 verified round on record; latest: $107 million Series B led by GV (Google Ventures) and Johnson & Johnson, announced 8 Jan 2026.

They develop bispecific antibodies designed to selectively degrade disease-causing extracellular proteins.

Website: https://epibiologics.com  
Page: https://fireround.dev/companies/epibiologics.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-01-08 | Series B | $107 million | GV (Google Ventures), Johnson & Johnson | Novartis, Polaris Partners, Samsara BioCapital | [biopharmadive.com](https://www.biopharmadive.com/news/epibiologics-series-b-targeted-protein-degradation-egfr/808984) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.